SEC Filings
State Street Holds 4.3% Of Viridian Therapeutics As Drugmaker Begins Commercial Sales
The September-end holding totaled 4,876,395 shares; Viridian reported $24.7 million from Lumvoa's first quarter on the market.
Viridian Therapeutics (VRDN) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The September-end holding totaled 4,876,395 shares; Viridian reported $24.7 million from Lumvoa's first quarter on the market.
SEC Filings
The company plans a myasthenia gravis trial in mid-2027, pending regulatory feedback, as it expands beyond thyroid eye disease.
Markets
Shares added $228 million in value as Lumvoa's launch topped 100 patients by September's end.
Earnings
More than 100 patients were on the thyroid eye disease drug at the end of September, while selling costs rose to $57.6 million.